ESMO open · 2025
Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Valenza C, Bianco N, Milano M, Trapani D, Di Bella S, Sciandivasci A, Minchella I, Sangalli C, Galimberti V, Intra M, Veronesi P, Munzone E, Colleoni M, Curigliano G
Аннотация
BACKGROUND: The role of breast surgery in patients with de novo metastatic breast cancer (mBC) and locoregional oligoprogression, either in the breast or locoregional lymph nodes, who previously had a response to systemic treatment is unknown. This approach may allow maintenance of the same systemic treatment and prolong the time to treatment failure.
PATIENTS AND METHODS: We conducted a cohort study including consecutive patients with de novo mBC, after a locoregional oligoprogression, who underwent breast surgery and continued the same systemic treatment at the European Institute of Oncology. The primary endpoint was postsurgery progression-free survival (pS-PFS).
RESULTS: Fifty-nine patients were included: 28 (47%) had hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative disease, 30 (51%) HER2-positive, and 1 (2%) triple-negative. The median pre-oligoprogression PFS was 15.2 months [95% confidence interval (CI) 12.0-18.4 months]. After a median follow-up of 54.1 months (95% CI 44.2-64.0 months), the median pS-PFSs was 15.0 months (95% CI 5.1-24.9 months), and was significantly longer in patients with HER2-positive disease or with a pre-oligoprogression PFS ≥12 months.
CONCLUSIONS: This study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.
PATIENTS AND METHODS: We conducted a cohort study including consecutive patients with de novo mBC, after a locoregional oligoprogression, who underwent breast surgery and continued the same systemic treatment at the European Institute of Oncology. The primary endpoint was postsurgery progression-free survival (pS-PFS).
RESULTS: Fifty-nine patients were included: 28 (47%) had hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative disease, 30 (51%) HER2-positive, and 1 (2%) triple-negative. The median pre-oligoprogression PFS was 15.2 months [95% confidence interval (CI) 12.0-18.4 months]. After a median follow-up of 54.1 months (95% CI 44.2-64.0 months), the median pS-PFSs was 15.0 months (95% CI 5.1-24.9 months), and was significantly longer in patients with HER2-positive disease or with a pre-oligoprogression PFS ≥12 months.
CONCLUSIONS: This study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.